Results 191 to 200 of about 44,864 (262)

Enhancing Optogenetics‐Based Cancer Therapy Via Nanotechnology

Exploration, EarlyView.
Nanotechnology enhances optogenetics‐based cancer therapy through improved delivery systems and non‐invasive optical regulation. It further enables precise and programmable control of optogenetic living therapeutics for localized antitumor responses.
Honggang Shen, Wenzhe Yi, Rongzhang Li, Shuangshuang Hu, Xindi Qian, Dan Yan, Qian Zou, Guanru Wang, Yaping Li   +8 more
wiley   +1 more source

Advances in natural killer cell immunotherapy for hematologic malignancies. [PDF]

Cancer Biol Ther
Hu H, Xiong Y, Xia M, Sheng L.
europepmc   +1 more source

Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19‐09, CONPELAN Study

Head &Neck, EarlyView.
ABSTRACT Background The benefit of consolidation programmed cell death protein 1 (PD‐1) blockade after chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. Methods Patients with stages II–IVB NPC were randomized (2:1) to pembrolizumab 200 mg or placebo every 3 weeks for up to 17 cycles after chemoradiotherapy ...
Sang Hoon Chun, Seyoung Seo, Jang Ho Cho, Keon‐Uk Park, Sang‐Cheol Lee, Yong Won Choi, Tak Yun, Seong Hoon Shin, Sung‐Bae Kim, Seungeun Lee, Chang Ho Ahn, Bhumsuk Keam   +11 more
wiley   +1 more source

Nanotechnology-Assisted Co-Delivery of Immunotherapeutic Agents for Targeting Ovarian Cancer: Prospects and Challenges. [PDF]

Int J Nanomedicine
Jiao L, Li M, Tan M, Zheng L, Liu Y, Cao Y.   +5 more
europepmc   +1 more source

Visualization of Scattered Tumor Regression Following Neoadjuvant Chemoimmunotherapy With a Novel Intraoperative PET/CT Scanner

Head &Neck, EarlyView.
ABSTRACT Background Neoadjuvant chemoimmunotherapy is being explored in locally advanced head and neck squamous cell carcinoma (HNSCC), yet the spatial patterns of pathologic response and clinical implications remain poorly characterized. Methods A 79‐year‐old female with recurrent left oral tongue SCC (PD‐L122C3 Combined Positive Score 90) who ...
Andreja Radevic, Joaquin Austerlitz, Ashtyn McAdoo, Kyrionna Golliday, Takeshi Takahashi, Mitra Mehrad, Adam J. Rosenberg, Barbara A. Murphy, Eben Rosenthal, Michael C. Topf   +9 more
wiley   +1 more source

Does immunotherapy hold great promise in endometrial cancer care? [PDF]

Front Immunol
Braszka M, Chowaniec H, Borowczyk M, Dwojak E, Stępień M, Ślubowska A, Mielczarek M, Markiewicz H, Ałtyn R, Zieliński P, Czerniak J, Adamczak O, Kluk A, Dworacki G, Dobosz P.   +14 more
europepmc   +1 more source

Exploring the Effects of Frailty and Sarcopenia on Dysphagia in Head and Neck Cancer: A Scoping Review

Head &Neck, EarlyView.
ABSTRACT Background Frailty and sarcopenia may influence head and neck cancer (HNC) treatment outcomes, including dysphagia. Current understanding of this relationship, however, remains limited. This scoping review aimed to synthesize existing evidence on the relationship between frailty and/or sarcopenia and dysphagia in adults with HNC.
Rishni Perera, Elizabeth C. Ward, Nicole O'Donnell, Paul Yates, Rebecca L. Packer   +4 more
wiley   +1 more source

Organoid models for T cell-based immunotherapy in hepatobiliary cancers. [PDF]

Hepatobiliary Surg Nutr
Du L, Dong J, Du S.
europepmc   +1 more source

Precision immuno-oncology in oral cancer: latest trends in biomarkers, novel drug development and nanoparticle-based therapeutic platforms. [PDF]

Front Cell Dev Biol
Augustine D, Sowmya SV, Pushpalatha C, Prasad K, Khatoon H.   +4 more
europepmc   +1 more source

Advances in Next-Generation Immunotherapies for Ovarian Cancer: Mechanisms of Immune Evasion and Novel Therapeutic Targets. [PDF]

Biomolecules
Rahman MA, Jalouli M, Al-Zharani M, Harrath AH.   +3 more
europepmc   +1 more source